Compare Acadia Healthcare Company Inc (ACHC) vs Gilead Sciences, Inc. (GILD) Price & Performance

ACHC trades at $31.53, up 2.64% today, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth with Q2 2026 earnings beating estimates, but faces profitability challenges with negative net income margins. Analyst consensus remains positive with 68% buy ratings and a $36 price target, though ongoing legal investigations create headwinds.

The outlook balances operational strength against financial risks. Revenue growth and facility expansion support upside potential, but negative profitability and legal uncertainties warrant caution. The stock offers 14% upside to consensus target if execution improves, but investors should monitor earnings sustainability and legal developments closely.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.